Raphael Pharmaceutical Inc. (RAPH) Form 10-Q — Aug 14, 2026
Raphael Pharmaceutical's 10-Q for the quarter ended June 30, 2026 discloses substantial doubt about the company's ability to continue as a going concern. The pre-revenue clinical-stage drug developer reported just $1,000 in cash and said existing funds will not cover projected requirements through the third quarter of 2026. Quarterly losses are shrinking but the company still has no revenue: Q2 net loss was $223,000, down 31% from $322,000 a year earlier, and the six-month net loss of $452,000 fell 40% from $751,000. Stockholders' equity is negative at $1.885 million against an accumulated deficit of $10.62 million.
Key figures
- Eps
- 0.02
- Revenue
- 0
- Net Income
- -$452K (six months ended June 30, 2026, vs -$751K prior year)
- Cash Position
- $1 thousand as of June 30, 2026 (vs $45 thousand at Dec 31, 2025)
- Q2 Eps
- $0.01 vs $0.02 prior year
- Q2 Net Loss
- $223,000, down 31% from $322,000 in Q2 2025
- Authorized Shares
- 50000000
- Shares Outstanding
- 20176418
- Accumulated Deficit
- $10,620 thousand
- Stockholders Deficit
- -$1,885 thousand
- Prior Authorized Shares
- 21020560
- Six Month Operating Loss
- $422,000, down 43% from $740,000
- Funding Need Next12 Months
- ~$1 million for R&D plus ~$1 million for clinical development, commercialization preparation and G&A
- Net Cash Used In Operations
- $44,000 (six months, vs $239,000 prior year)
- Related Party Loan Balance
- NIS 127.2 thousand (~$42.7 thousand)
- Rambam Outstanding Balance
- ~$319,000 plus VAT
- Related Party Payables Officers
- $1,310 thousand
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.